BioNexus Gene Lab Corp announces a strategic partnership with BirchBioMed to advance the FS2 topical platform in Southeast Asia.
Quiver AI Summary
BioNexus Gene Lab Corp (BGLC) has announced a non-binding strategic partnership with BirchBioMed Inc., a Canadian biopharmaceutical company, to enhance the commercialization of Birch's FS2 topical platform in Southeast Asia. This collaboration will involve BGLC leading a $10 million financing round for Birch through a strategic equity investment, where BGLC will issue shares in exchange for 1.5 million shares of Birch. BGLC will also provide market intelligence and support in regulatory and clinical trial strategies. Both parties aim to negotiate a definitive agreement, with BGLC CEO Sam Tan and Birch CEO Mark S. Miller expressing optimism about the partnership's potential to advance innovative therapies in the region. The announcement includes typical forward-looking statements regarding the partnership's future developments and risks.
Potential Positives
- BioNexus Gene Lab Corp is leading a $10 million financing round for BirchBioMed Inc., enhancing its position in the burgeoning market for regenerative medicine in Southeast Asia.
- The partnership aims to leverage BGLC's regional market access and infrastructure with Birch's innovative FS2 topical platform, potentially accelerating commercialization in Malaysia and Singapore.
- BGLC's strategic investment includes issuing common shares, which represents a significant commitment to Birch’s growth and aligns with BGLC's goal of expanding its portfolio in precision therapeutics.
Potential Negatives
- The non-binding nature of the Strategic Partnership Term Sheet raises concerns about the commitment level of both parties and the likelihood of successful execution of a definitive agreement.
- There is no assurance that the proposed transactions will be completed on the terms contemplated or at all, indicating potential uncertainty for stakeholders.
- The press release includes a disclaimer about forward-looking statements, highlighting risks and uncertainties that could negatively impact the anticipated benefits of the partnership and its commercialization objectives.
FAQ
What is the recent partnership between BioNexus Gene Lab and BirchBioMed?
BioNexus Gene Lab announced a non-binding strategic partnership with BirchBioMed to help commercialize Birch's FS2 topical platform in Southeast Asia.
How much is BirchBioMed's upcoming financing round?
BirchBioMed's upcoming financing round is set at USD $10 million, led by BioNexus Gene Lab through a strategic equity investment.
What will BioNexus Gene Lab provide to BirchBioMed?
BioNexus Gene Lab will offer market intelligence, regulatory guidance, and assistance in securing partners for Birch's FS2 topical cream.
What is the FS2 topical platform developed by BirchBioMed?
The FS2 topical platform is a product that targets dermal fibrosis and scarring using a proprietary formulation of kynurenic acid.
What are the next steps in the partnership between BGLC and BirchBioMed?
Both companies will negotiate a definitive agreement, ensuring customary representations and warranties, although the term sheet is currently non-binding.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BGLC Hedge Fund Activity
We have seen 0 institutional investors add shares of $BGLC stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 9,877 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $30,322
- TWO SIGMA INVESTMENTS, LP removed 3,553 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $10,907
- GEODE CAPITAL MANAGEMENT, LLC removed 2,368 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $7,269
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
KUALA LUMPUR, Malaysia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, “BGLC”, or the “Company”), today announced that it has entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. (“Birch”), a Canadian biopharmaceutical company developing regenerative treatments for organ fibrosis, topical scarring and autoimmune diseases.
Under the non-binding term sheet, BGLC would lead Birch’s USD $10 million upcoming financing round through a strategic equity investment and collaboration to accelerate commercialization of Birch’s FS2 (kynurenic acid) topical platform in Southeast Asia. The partnership is designed to combine BGLC’s regional market access and infrastructure with Birch’s novel science in dermal regeneration and fibrosis control.
Key Proposed Terms
- Strategic Investment & Equity Exchange : BGLC would issue common shares representing 4.99 percent of its outstanding common shares to Birch as its lead investment in Birch’s current financing round. In consideration, Birch would issue 1.5 million common shares of Birch to BGLC.
- Strategic Support : BGLC would provide Birch with market intelligence, regulatory and clinical-trial strategy guidance, and assistance in securing licensees and commercialization partners for the FS2 topical cream in Malaysia and Singapore.
-
Next Steps
: Both parties intend to negotiate a definitive agreement containing customary representations, warranties, and closing conditions.
The Term Sheet is non-binding, except for its exclusivity and confidentiality provisions, which are binding for 60 days from execution. There can be no assurance that a definitive agreement will be executed or that the proposed transactions will be completed on the terms contemplated or at all.
Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp
, commented:
“This strategic framework with BirchBioMed reflects our commitment to partnering with leading biotech innovators to bring clinically validated therapies to Asia in a capital-efficient manner. We see Birch’s FS2 platform as an exciting addition to our growing portfolio in regenerative medicine and precision therapeutics.”
Mark S. Miller, Chairman and Chief Executive Officer of BirchBioMed Inc.
, added:
“We are delighted to partner with BioNexus Gene Lab to advance the regional rollout of our FS2 topical platform. BGLC’s established infrastructure and clinical expertise in Southeast Asia provide an ideal foundation to accelerate access to our scar-reduction and skin-regeneration technology. Together we aim to deliver meaningful therapeutic innovation and broaden FS2’s global reach.”
About BioNexus Gene Lab Corp (Nasdaq: BGLC)
BioNexus Gene Lab Corp is a Wyoming-incorporated biotechnology company focused on precision diagnostics, gene-based technologies, and biologics. Through its subsidiaries MRNA Scientific Sdn. Bhd. and Chemrex Corporation Sdn. Bhd., BGLC develops innovative platforms for biotechnology and high-tech manufacturing solutions across Asia. More information is available at www.bionexusgenelab.com.
About BirchBioMed Inc.
BirchBioMed Inc. is a clinical-stage biopharmaceutical company headquartered in Vancouver, Canada, dedicated to developing novel therapeutics for autoimmune diseases, organ fibrosis, and topical scarring. Birch’s lead product, FS2 topical cream, targets dermal fibrosis and scarring through a proprietary formulation of kynurenic acid (KynA). For more information, visit www.birchbiomed.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential strategic partnership with BirchBioMed Inc., the negotiation of definitive agreements, future financing plans, and commercialization objectives. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause actual results to differ include risks associated with the negotiation of definitive agreements, regulatory approvals, capital-raising, and commercialization of new technologies. BGLC undertakes no obligation to update or revise any forward-looking statement, except as required by law.
Investor & Media Contact
Investor Relations Department
BioNexus Gene Lab Corp
Email: [email protected]
Website: www.bionexusgenelab.com
